Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer: Outcome analysis and comparison with a 3D-treated patient cohort

Strahlentherapie und Onkologie

Volumn 189, Issue 9, 2013, Pages 738-744

  Combs, S E ^a   Habermehl, D ^a   Kessel, K ^a   Bergmann, F ^a   Werner, J ^a   Brecht, I ^a   Schirmacher, P ^a   Jager D ^b   Buchler M W ^a   Debus, J ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

3D conformal radiotherapy; Intensity modulated radiotherapy; Locally advanced pancreatic cancer; Neoadjuvant treatment; Toxicity

Indexed keywords

GEMCITABINE;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; COMPUTER ASSISTED RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; AGED; CHEMORADIOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; TREATMENT OUTCOME;

EID: 84883273975     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-013-0391-5     Document Type: Article

References (41)

1. Gillen S, Schuster T, Meyer Zum BC et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267
2. Habermehl D, Lindel K, Rieken S et al (2012) Chemoradiation in patients with unresectable extrahepatic and hilar cholangiocarcinoma or at high risk for disease recurrence after resection: analysis of treatment efficacy and failure in patients receiving postoperative or primary chemoradiation. Strahlenther Onkol 188:795-801
3. Milano MT, Garofalo MC, Chmura SJ et al (2006) Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. Br J Radiol 79:497-503
4. Milano MT, Jani AB, Farrey KJ et al (2005) Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 63:354-361
5. Chandra A, Guerrero TM, Liu HH et al (2005) Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol 77:247-253
6. Gomez DR, Tucker SL, Martel MK et al (2012) Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 84:1010-1016
7. Jiang ZQ, Yang K, Komaki R et al (2012) Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys 83:332-339
8. Lin SH, Wang L, Myles B et al (2012) Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys
9. Wang SL, Liao Z, Liu H et al (2006) Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. World J Gastroenterol 12:5501-5508
10. Welsh J, Gomez D, Palmer MB et al (2011) Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys 81:1336-1342
11. Welsh J, Palmer MB, Ajani JA et al (2012) Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys 82:468-474
12. Zhang X, Zhao KL, Guerrero TM et al (2008) Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys 72:278-287
13. Milano MT, Chmura SJ, Garofalo MC et al (2004) Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 59:445-453
14. Yovino S, Poppe M, Jabbour S et al (2011) Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. Int J Radiat Oncol Biol Phys 79:158-162
15. Crane CH, Winter K, Regine WF et al (2009) Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol 27:4096-4102
16. Ben Josef E, Shields AF, Vaishampayan U et al (2004) Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 59:454-459
17. Krempien R, Muenter MW, Huber PE et al (2005) Randomized phase II - study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer - PARC: study protocol [ISRCTN56652283]. BMC Cancer 5:131
18. Habermehl D, Kessel K, Welzel T et al (2012) Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat Oncol 7:28
19. Sangalli G, Passoni P, Cattaneo GM et al (2011) Planning design of locally advanced pancreatic carcinoma using 4DCT and IMRT/IGRT technologies. Acta Oncol 50:72-80
20. Ben Josef E, Schipper M, Francis IR et al (2012) A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys
21. Yovino S, Maidment BW III, Herman JM et al (2012) Analysis of local control in patients receiving IMRT for resected pancreatic cancers. Int J Radiat Oncol Biol Phys 83:916-920
22. Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363:1049-1057
23. Buchler MW, Kleeff J, Friess H (2007) Surgical treatment of pancreatic cancer. J Am Coll Surg 205:S81-S86
24. Allison DC, Piantadosi S, Hruban RH et al (1998) DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol 67:151-159
25. Allison DC, Bose KK, Hruban RH et al (1991) Pancreatic cancer cell DNA content correlates with long-term survival after pancreatoduodenectomy. Ann Surg 214:648-656
26. Sohn TA, Yeo CJ, Cameron JL et al (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567-579
27. Howard TJ, Krug JE, Yu J et al (2006) A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 10:1338-1345
28. Moertel CG, Frytak S, Hahn RG et al (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48:1705-1710
29. Varadhachary GR, Wolff RA, Crane CH et al (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26:3487-3495
30. Varadhachary GR, Tamm EP, Abbruzzese JL et al (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13:1035-1046
31. Murphy JD, Adusumilli S, Griffith KA et al (2007) Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68:801-808
32. Girard N, Mornex F, Bossard N et al (2010) Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial. Int J Radiat Oncol Biol Phys 77:1426-1432
33. Shibuya K, Oya N, Fujii T et al (2010) Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer. Am.J.Clin.Oncol
34. Murphy JD, Adusumilli S, Griffith KA et al (2007) Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68:801-808
35. Crane CH, Wolff RA, Abbruzzese JL et al (2001) Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin Oncol 28:25-33
36. Mukherjee S, Hurt CN, Bridgewater J et al (2013) Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 14:317-326
37. Haddock MG, Swaminathan R, Foster NR et al (2007) Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol 25:2567-2572
38. Pingpank JF, Hoffman JP, Ross EA et al (2001) Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg 5:121-130
39. Kessel KA, Habermehl D, Bohn C et al (2012) Database supported electronic retrospective analyses in radiation oncology: establishing a workflow using the example of pancreatic cancer. Strahlenther Onkol 188:1119-1124
40. Kessel KA, Habermehl D, Jäger A, Floca RO et al (2013) Development and validation of automatic tools for interactive recurrence analysis in radiation therapy: optimization of treatment algorithms for locally advanced pancreatic cancer. Radiat Oncol 8:138
41. Golden DW, Novak CJ, Minsky BD, Liauw SL (2012) Radiation dose ≥ 54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation. Radiat Oncol 7:156